Literature DB >> 4133839

Clinical trial with subcutaneously administered 5-azacytidine (NSC-102816).

R E Bellet, M J Mastrangelo, P F Engstrom, J G Strawitz, A J Weiss, J W Yarbro.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4133839

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN： 0069-0112


× No keyword cloud information.
  5 in total

Review 1.  Epigenetic therapy of leukemia: An update.

Authors:  Nitin Jain; Adriana Rossi; Guillermo Garcia-Manero
Journal:  Int J Biochem Cell Biol       Date:  2008-10-17       Impact factor: 5.085

2.  Effects of DNA methylation on expression of tumor suppressor genes and proto-oncogene in human colon cancer cell lines.

Authors:  Jing-Yuan Fang; Juan Lu; Ying-Xuan Chen; Li Yang
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

Review 3.  Treatment options in advanced myelodysplastic syndrome, with emphasis on epigenetic therapy.

Authors:  Yasuhiro Oki; Jean-Pierre J Issa
Journal:  Int J Hematol       Date:  2007-11       Impact factor: 2.490

Review 4.  Safety and efficacy of azacitidine in myelodysplastic syndromes.

Authors:  Carlos E Vigil; Taida Martin-Santos; Guillermo Garcia-Manero
Journal:  Drug Des Devel Ther       Date:  2010-09-24       Impact factor: 4.162

Review 5.  Demethylating Agents in the Treatment of Cancer.

Authors:  Paul M Howell; Zixing Liu; Hung T Khong
Journal:  Pharmaceuticals (Basel)       Date:  2010-07-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.